Guide to Pharmacology contains curated information on SARS-CoV-2 targets and captures some of the pharmacological strategies being investigated to mitigate against COVID-19. New ligands are being posted to a pre-release blog.

Services offered by other infrastructures

CIISB (Czech Infrastructure for Integrative Structural Biology) offers priority access to research groups, which need to use the CIISB structural biology services for R&D projects directly related to the studies of the SARS-CoV-2 virus and projects aiming to develop an effective vaccine and/or treatment of Covid-19 disease.

IT4Innovations National Supercomputing Centre at VŠB – Technical University of Ostrava has offered its users from academic institutions priority access to its computational resources to solve problems regarding the Covid-19 disease research.

BBMRI-ERIC – Resources from biobanks across Europe: The network of 600+ biobanks presents a list of those BBMRI national nodes and biobanks that provided specific information on the resources they can make available to researchers (academic and from the private sector) working on COVID-19. (Details about the service here).

EU-OPENSCREEN’s partner sites are currently engaged in a range of activities to study the new coronavirus SARS-CoV-2 with focus on drug discovery including screening campaigns of local repurposing libraries. (Details about the service here).

EATRIS-ERIC – Fast access to services and facilities: EATRIS provides key services for researchers and/or research teams (academic or industrial) that are developing a potential therapy, vaccine or tool for use against the current COVID-19 pandemic, with secured funding. Read here EATRIS Members’ COVID-19 activities and services. (Details about the service here).